Q32 Bio reports positive 36-week Phase 2a data for bempikibart in alopecia areata
Q
QTTB• Q32 Bio reported positive Week 36 topline Phase 2a results for bempikibart in severe alopecia areata in the open-label SIGNAL-AA Part B trial.
- Primary endpoint met in the prespecified mITT analysis, with a 35.3% mean reduction in SALT score from baseline.
- SALT-20 response reached 40% in mITT (10/25) versus 30.3% in ITT (10/33), supporting efficacy in a broader enrolled population.
- Safety profile remained consistent with prior studies, with no new safety signals or treatment-related serious adverse events.
- Program strategy updated, with a registration-directed development plan targeted for the first half of 2027.
